My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

AbbVie Inc. (ABBV) — RQD Stock Rating Cockpit

$283.51 -0.87% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $283.75

AbbVie Inc. (ABBV) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (70.2% gross margin, 29% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $501.14B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABBV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABBV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, AbbVie Inc. (NYSE: ABBV) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $283.51 (-0.87% 1D, market cap $501.14B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, ABBV ranks #15 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABBV compare to JNJ and MRK in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABBV carries a Roarable B+ (76/100 RQD), trailing P/E of 121.6x, gross margin of 70.2%, and ROIC of 29.0%. By comparison, JNJ (Johnson & Johnson) holds a B+ grade (76/100 RQD, P/E 24.7x, ROIC 25.5%, cap $642.99B) and MRK (Merck & Company Inc.) posts a C+ grade (69/100 RQD, P/E 19.8x, ROIC 20.7%, cap $327.24B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABBV?
▼

Per ABBV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001551152), AbbVie Inc. generated $61.16B in revenue (+8.6% YoY), $4.23B in net income, and $17.82B in free cash flow against $133.96B in total assets and $31.35B in total debt. Key quantitative strengths: Strong cash generator (70.2% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 122x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 ABBV TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $ABBV, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $ABBV R/R 3.6 : 1 • RQD 76/100 (B+)
$ABBV
Spot $283.51
1. GET IN (ENTRY)
$281.81–$284.93
2. HARD STOP (SUP)
$271.89 (-4.1%)
3. GET OUT (T1/T2)
$308.46 / $325.47
STOP-LOSS FLOOR (SUP $271.89): Hard stop sits 4.1% below spot to cap downside below key institutional support. If $ABBV closes a daily candle below $271.89, step aside.
PROFIT TARGETS (RES $308.46 / $325.47): Scale out 50% at T1 (+8.8%) and trail stop to breakeven for T2 (+14.8%).
Want this $ABBV sheet + Today's Top 3 Trades emailed free? Paper Trade $ABBV →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $ABBV Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $283.74 (+0.08%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 29.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510076
3-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B+ · Rk B
Cash (18)Whales (15)SEC (16)Macro (14)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+8.1% Base Target
$362 Bull$306 Base$232 Bear
📬 FREE ABBV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABBV)Realized 20D OHLCV Swing Band: ±2.3%
Deterministic 5-Pillar Attribution (76/100 Composite)
🔍 WHY ABBV SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 29.1% FCF Margin ($17.82B FCF) & 70.2% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)

Altman Z-Score 5.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution13/20 pts (-7 pt drag)

Cannibal Buyback (-1.52% YoY Shares) & executive Form 4 sales trim 7 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
84
Grade A$288.70+1.8% Next Q
Q2 (-2Q)
81
Grade A-$293.97+0.4% Next Q
Q3 (-1Q)
79
Grade A-$295.17-4% Next Q
Current
76
Grade B+$283.51+7.6% Hist 90D α
Trajectory: A (84) → B+ (76)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ABBV Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, ABBV faces multiple-compression risk if 121.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 122x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 67.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($281.90) or 200D SMA ($244.16) invalidates the momentum regime and cuts Target Base ($306.47) toward Bear Floor ($232.48).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABBV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABBV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
40.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
5.33>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE86% OF RANGE
L: $191$283.51H: $299
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (70.2% gross margin and healthy balance-sheet cushion).

Factor Grade: ARQD 18 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B-RQD 28 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bullish on ABBV

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (90)

29.0% ROIC with 70.2% gross margin and 3.47% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 5.33 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (70)

28/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like ABBV
  • ✓Strong cash generator (70.2% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Priced at 122x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ABBV Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABBV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +33.03%🛡️ HOLDING TREND SUPPORT
2026-11-22O $286.0H $286.0L $283.5C $283.5VOL 5.05M
$305.1$278.8$252.5$226.2$199.9RES $311.2SUP $278.4$283.52026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE WIDE ECONOMIC MOAT (ROIC 29.0% vs WACC 7.2%)

ABBV Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $303.15 vs Spot $283.51
MODESTLY UNDERVALUED (+6.5%)
Undervalued Zone (< $258) Fair Value Corridor ($258–$349) Overvalued (> $349)
$284
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own ABBV Growth & WACC Assumptions

YOUR DCF TARGET
$524.49
5-Yr Annual FCF Growth Rate: 24.4%
Discount Rate (WACC Hurdle): 7.2%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: +6.5% vs $283.51 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABBV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +8.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABBV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABBV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABBV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABBV)

Health Care Rank #15 of 1015 ⚔️ JNJ vs ABBV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABBV vs. JNJ, MRK, NVS, AZN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AbbVie Inc. (ABBV) ranks #15 by composite RQD confidence (76/100, grade B+) and #3 by equity capitalization ($501.14B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. ABBV currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ABBV ACTIVE
AbbVie Inc.
B+ 76/100 121.6x 70.2% 29.0% -0.87% $501.14B Benchmark Subject
JNJ
Johnson & Johnson
B+ 76/100 24.7x 67.9% 25.5% -2.05% $642.99B /jnj-vs-abbv →
MRK
Merck & Company Inc.
C+ 69/100 19.8x 74.8% 20.7% -3.66% $327.24B /mrk-vs-abbv →
NVS
Novartis AG
D+ 56/100 32.8x — 9.9% -2.55% $288.61B /nvs-vs-abbv →
AZN
AstraZeneca PLC
D+ 56/100 32.8x — 9.9% -1.91% $271.90B /azn-vs-abbv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001551152 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AbbVie Inc. (ABBV) reported GAAP revenue of $61.16B (+8.6% vs. FY2024 revenue of $56.33B , and +12.6% cumulative change since FY2023) , GAAP net income of $4.23B, operating cash flow of $19.03B, and free cash flow of $17.82B (-0.1% YoY). On the balance sheet, ABBV closed FY2025 with $133.96B in total assets against $31.35B in total debt (Altman Z-Score: 5.33, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $61.16B $4.23B $19.03B $17.82B $133.96B $31.35B
FY2024 (FY) 2024-12-31 $56.33B $4.28B $18.81B $17.83B $135.16B $31.63B
FY2023 (FY) 2023-12-31 $54.32B $4.86B $22.84B $20.39B $282.62B $66.13B

3. ABBV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABBV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, AbbVie Inc. (NYSE: ABBV) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $283.51 (-0.87% 1D, market cap $501.14B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, ABBV ranks #15 in composite RQD confidence.

How does ABBV compare to JNJ and MRK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABBV carries a Roarable B+ (76/100 RQD), trailing P/E of 121.6x, gross margin of 70.2%, and ROIC of 29.0%. By comparison, JNJ (Johnson & Johnson) holds a B+ grade (76/100 RQD, P/E 24.7x, ROIC 25.5%, cap $642.99B) and MRK (Merck & Company Inc.) posts a C+ grade (69/100 RQD, P/E 19.8x, ROIC 20.7%, cap $327.24B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABBV?

Per ABBV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001551152), AbbVie Inc. generated $61.16B in revenue (+8.6% YoY), $4.23B in net income, and $17.82B in free cash flow against $133.96B in total assets and $31.35B in total debt. Key quantitative strengths: Strong cash generator (70.2% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 122x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABBV trading relative to its 50-day, 200-day, and 52-week technical levels?

ABBV last traded at $283.51 (-0.87% on volume of 5,047,453 shares), positioning the stock +0.57% above its 50-day simple moving average ($281.90) and +16.12% above its 200-day simple moving average ($244.16). Across its 52-week range of $190.75 to $298.74, ABBV sits at the 85.9% percentile with a 14-day RSI of 40.6 (NEUTRAL RANGE) and an implied next-earnings move of ±2.3% ($276.99 to $290.03).

ROARABLE RATING BRIEF • RQD 76/100 (B+) ✓ SEC XBRL & RQD VERIFIED

ABBV — AbbVie Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AbbVie Inc. (ABBV) earns a live Roarable RQD composite score of 76/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $283.51 (-0.87% 1D, market capitalization $501.14B).

  • Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 29.0%, gross margin of 70.2%, operating margin of 24.6%, and free cash flow yield of 3.47%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (16/20): Incorporates a 1.15x equity beta, Altman Z-Score of 5.33, Piotroski F-Score of 7/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

AbbVie Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AbbVie Inc. (ABBV) reported $61.16B in annual revenue (up from $56.33B in FY2024, +8.6% YoY) and $4.23B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($54.32B revenue, $4.86B net income) through FY2025, ABBV scaled operating cash flow to $19.03B and free cash flow to $17.82B, backed by $133.96B in total assets against $31.35B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B+ • RQD 76/100): Strong cash generator (70.2% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $190.75 – $298.74 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 122x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 121.6x trailing P/E and 33.3x EV/EBITDA against 24.6% operating margins and a 1.15x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The investor implication is that the source provides no mapped second-order exposures, so any ripple analysis would fall outside the supplied evidence.

  • Key Question #1: Can ABBV sustain or expand its 24.6% operating margin and 29.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $61.16B and free cash flow of $17.82B, how will capital allocation balance growth reinvestment against $31.35B in total debt?
  • Key Question #3: How sensitive is ABBV's 113.1x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.15x)?

ABBV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AbbVie Inc. (ABBV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABBV Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABBV Bull vs. Bear Conversation Board — What's Your Call at $283.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABBV 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ABBV:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $339.12 (+15.0%)
📌 Pinned Debate

ROIC of 29% and a 19/20 whale-flow pillar signal strong capital efficiency and institutional accumulation.

ROIC of 29% and a 19/20 whale-flow pillar signal strong capital efficiency and institutional accumulation.. When you look under the hood at ABBV, Fundamental Cash Engine is 18/20 with 70.2% gross margins and 29.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (20/20) has been quietly accumulating below $298.74. My 12M target is $339.12.

VolSurface_Trader 🐂 BULL

Both sides have a point here — ABBV's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $241.81 (-18.0%)
Spot @ $294.89

A P/E (TTM) of 121.6 and an FCF yield of 3.47% leave little valuation cushion against the 1.15 beta.

Here is the bear case nobody on the bull side wants to address on ABBV: A P/E (TTM) of 121.6 and an FCF yield of 3.47% leave little valuation cushion against the 1.15 beta.. At 121.6x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
LIVE TAPE